Literature DB >> 29468284

Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.

Mihai Dorin Vartolomei1,2,3, Shoji Kimura1,4, Matteo Ferro3, Liliana Vartolomei1, Beat Foerster1,5, Mohammad Abufaraj1,6, Shahrokh F Shariat7,8,9,10.   

Abstract

BACKGROUND: Preoperative blood-based inflammatory biomarkers have been suggested to improve staging and prognostication in patients with upper-tract urothelial carcinoma (UTUC). Neutrophil-to-lymphocyte ratio (NLR) is the most studied blood-based biomarker. NLR is an indicator of systemic inflammation and has been shown to be associated with a poor prognosis in various malignancies. The aim of this study was to analyze the current evidence regarding the prognostic significance of preoperative NLR in patients undergoing radical nephroureterectomy (RNU) for UTUC to assess its prognostic potential.
MATERIALS AND METHODS: A systematic search of Web of Science, Medline/PubMed and Cochrane library was performed on the 1st of October, 2017. Studies were deemed eligible if they compared patients with high NLR before surgical treatment for UTUC to patients with low NLR to determine its predictive value for survival using multivariable logistic regression analysis. We performed a formal meta-analysis for cancer-specific survival (CSS), recurrence-free survival (RFS) and overall survival (OS).
RESULTS: Nine studies including a total of 4385 patients assessing the importance of NLR were included in this meta-analysis. The cut-off NLR varied in the eligible studies ranging from 2 to 3. Increased pretreatment NLR predicted OS (pooled HR 1.64 95% CI; 1.23-2.17), RFS (pooled HR 1.60 95% CI; 1.16-2.20) and CSS (pooled HR 1.73 95% CI; 1.23-2.44) in multivariable analyses.
CONCLUSION: In this meta-analysis, preoperative blood-based NLR is associated with worse prognosis in patients who underwent RNU for UTUC. NLR could be used to improve clinical decision making regarding RNU vs. kidney-sparing surgery, extent of lymphadenectomy, perioperative systemic therapy and follow-up schedule.

Entities:  

Keywords:  Biomarker; Cancer-specific survival; Neutrophil-to-lymphocytes ratio; Recurrence

Mesh:

Substances:

Year:  2018        PMID: 29468284     DOI: 10.1007/s00345-018-2235-5

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  47 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

3.  Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Jiwei Huang; Yichu Yuan; Yanqing Wang; YongHui Chen; Wen Kong; Wei Xue; Haige Chen; Jin Zhang; Yiran Huang
Journal:  Urol Oncol       Date:  2017-08-18       Impact factor: 3.498

Review 4.  High Neutrophil-to-lymphocyte Ratio as Prognostic Factor in Patients Affected by Upper Tract Urothelial Cancer: A Systematic Review and Meta-analysis.

Authors:  Michele Marchioni; Luca Cindolo; Riccardo Autorino; Giulia Primiceri; Davide Arcaniolo; Marco De Sio; Luigi Schips
Journal:  Clin Genitourin Cancer       Date:  2016-12-29       Impact factor: 2.872

5.  Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study.

Authors:  Kazumasa Matsumoto; Giacomo Novara; Amit Gupta; Vitaly Margulis; Thomas J Walton; Marco Roscigno; Casey Ng; Eiji Kikuchi; Richard Zigeuner; Wassim Kassouf; Hans-Martin Fritsche; Vincenzo Ficarra; Guido Martignoni; Stefan Tritschler; Joaquin Carballido Rodriguez; Christian Seitz; Alon Weizer; Mesut Remzi; Jay D Raman; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Pierre I Karakiewicz; Christopher G Wood; Francesco Montorsi; Masatsugu Iwamura; Shahrokh F Shariat
Journal:  BJU Int       Date:  2011-04-20       Impact factor: 5.588

6.  Prognostic Role of Neutrophil-to-lymphocyte Ratio-based Markers During Pre- and Postadjuvant Chemotherapy in Patients With Advanced Urothelial Carcinoma of Upper Urinary Tract.

Authors:  Minyong Kang; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Clin Genitourin Cancer       Date:  2017-01-12       Impact factor: 2.872

7.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Authors:  Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

8.  The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Nozomu Kishimoto; Tetsuya Takao; Sohei Kuribayashi; Gaku Yamamichi; Kosuke Nakano; Masataka Kawamura; Koichi Tsutahara; Go Tanigawa; Seiji Yamaguchi
Journal:  Int J Clin Oncol       Date:  2016-09-10       Impact factor: 3.402

Review 9.  Cancer-related inflammation and treatment effectiveness.

Authors:  Connie I Diakos; Kellie A Charles; Donald C McMillan; Stephen J Clarke
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

10.  Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome.

Authors:  Hao-Lun Luo; Yen-Ta Chen; Yao-Chi Chuang; Yuan-Tso Cheng; Wei-Ching Lee; Chih-Hsiung Kang; Po-Hui Chiang
Journal:  BJU Int       Date:  2014-03-14       Impact factor: 5.588

View more
  17 in total

Review 1.  Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Michael Rink; David D'Andrea; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Turk J Urol       Date:  2020-10-09

2.  Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis.

Authors:  Jialin Li; Yusheng Cheng; Zhigang Ji
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

3.  Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.

Authors:  Akinori Nukui; Takao Kamai; Kyoko Arai; Toshiki Kijima; Minoru Kobayashi; Takahiro Narimatsu; Tsunehito Kambara; Hideo Yuki; Hironori Betsunoh; Hideyuki Abe; Yoshitatsu Fukabori; Masahiro Yashi; Ken-Ichiro Yoshida
Journal:  Cancer Immunol Immunother       Date:  2020-02-06       Impact factor: 6.968

4.  Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma.

Authors:  Hang Xu; Jian-Zhong Ai; Ping Tan; Tian-Hai Lin; Xi Jin; Li-Na Gong; Hao-Ran Lei; Lu Yang; Qiang Wei
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

5.  Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis.

Authors:  Yuhai Bao; Yin Wang; Xiaodong Li; Mingjun Pan; Hongze Zhang; Zegen Cheng; Xueyi Wang
Journal:  Cancer Cell Int       Date:  2019-11-27       Impact factor: 5.722

6.  Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society.

Authors:  Joyce Baard; Merve Celebi; Jean de la Rosette; Antonio Alcaraz; Shahrokh Shariat; Luigi Cormio; Vítor Cavadas; M Pilar Laguna
Journal:  JMIR Res Protoc       Date:  2020-01-24

7.  Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma.

Authors:  Shota Omura; Satoru Taguchi; Shogo Miyagawa; Ryuki Matsumoto; Mio Samejima; Naoki Ninomiya; Kazuki Masuda; Yu Nakamura; Tsuyoshi Yamaguchi; Manami Kinjo; Mitsuhiro Tambo; Takatsugu Okegawa; Eiji Higashihara; Hiroshi Fukuhara
Journal:  BMC Urol       Date:  2020-08-28       Impact factor: 2.264

8.  Combination of Systemic Inflammation Response Index and Platelet-to-Lymphocyte Ratio as a Novel Prognostic Marker of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.

Authors:  Yangqin Zheng; Yuming Chen; Jingfeng Chen; Wu Chen; Yue Pan; Lianmin Bao; Xiaomin Gao
Journal:  Front Oncol       Date:  2019-09-18       Impact factor: 6.244

9.  Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Authors:  Meghan A Cupp; Margarita Cariolou; Ioanna Tzoulaki; Dagfinn Aune; Evangelos Evangelou; Antonio J Berlanga-Taylor
Journal:  BMC Med       Date:  2020-11-20       Impact factor: 8.775

10.  The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence.

Authors:  Ruining Zhao; Jiahao Shan; Lihong Nie; Xiaobo Yang; Zhongyu Yuan; Haoran Xu; Ziyang Liu; Xiaojie Zhou; Wenzhuo Ma; Hongbin Shi
Journal:  J Clin Lab Anal       Date:  2021-06-29       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.